Table 1 Characteristics of patient cohorts
Characteristic | 1996-97 | 2001-03 | 2009-10 | 2012-14 |
|---|---|---|---|---|
n = 189 | n = 310 | n = 304 | n = 520* | |
Female gender, n (%) | 140 (74 %) | 237 (76 %) | 244 (80 %) | 413 (79 %) |
Age, mean (SD) | 59 (14) | 60 (13) | 59 (15) | 58 (15) |
Disease duration in years, median (IQR) | 8 (13) | 9 (10) | 10 (9) | 10 (9) |
Any DMARD, n (%) | 115 (61 %) | 199 (64 %) | 242 (80 %) | 420 (87 %) |
Combination DMARDs, n (%) | 1 (1 %) | 31 (10 %) | 65 (21 %) | 199 (41 %) |
Biologic users, n (%) | 0 | 11 (4 %) | 53 (17 %) | 155 (32 %) |
Oral steroids, n (%) | 23 (12 %) | 70 (23 %) | 30 (10 %) | 56 (12 %) |
DAS, mean (SD) | 5.2 (1.6) | 4.7 (1.6) | 3.8 (1.5) | 3.7 (1.6) |
Tender joint count, mean (SD) | 10.1 (9.2) | 7.5 (7.3) | 4.1 (5.6) | 4.2 (6.2) |
Swollen joint count, mean (SD) | 7.1 (5.5) | 4.8 (4.1) | 2.9 (4.2) | 1.5 (2.7) |
Patient global, mean (SD) | 50 (25) | 50 (29) | 40 (25) | 35 (28) |
ESR, mean (SD) | 35 (26) | 33 (27) | 26 (21) | 19 (21) |
HAQ score, median (IQR) | 1.30 (1.52) | 1.52 (0.79) | Not available | 1.32 (0.84) |
Pain, Mean (SD) | 50 (24) | 48 (28) | Not available | 44 (28) |
Fatigue, Mean (SD) | Not available | 50 (28) | Not available | 51 (26) |